Skin cancer drug pembrolizumab hailed as 'miraculous' new treatment

'Promising treatment' revealed to boost survival rates of melanoma from one in ten to nearly three in four

A pioneering new drug appears to have cured a British man with advanced skin cancer who had been given just months to live.

Doctors cannot be certain it was the treatment that led to the "miraculous" outcome for 64-year-old Warwick Steele, but know of no other explanation.

Results from an early-stage trial of the drug indicate that it may offer a potential "paradigm shift" in cancer therapy, according to Mr Steele's consultant.

The drug, pembrolizumab, is the latest in a new generation of treatments that prevent cancers shielding themselves from the immune system.

It was tested on melanoma - the most dangerous form of skin cancer - because the prospects for patients with advanced forms of this disease are so bleak.

Just under 70 per cent of the 411 patients taking part in the trial were still alive one year after starting on the treatment.

The result is considered remarkable because all had highly advanced melanoma and a very poor prognosis.

Currently one-year survival rates for untreated patients diagnosed with advanced stage four melanoma are just 10% for men and 35% for women.

Mr Steele, a television engineer from Ruislip, west London, had undergone six months of treatment with pembrolizumab, which is injected into the bloodstream.

Doctors were astonished when after just three months his tumours had almost disappeared. Since then they have shown no sign of returning - and in fact have shrunk even further.

His consultant, Dr David Chao, from the Royal Free Hampstead NHS Trust in London, said: "We cannot say for certain that he's been cured, but he is doing very well. He was aware that without an effective treatment his survival prospects were not good - maybe months.

"Pembrolizumab looks like it has potential to be a paradigm shift for cancer therapy and is firmly helping to establish immunotherapy as one of the most exciting and promising treatment modalities in recent years.

"This is one of several new drugs of this type being produced. What these early trials are showing is that they are fulfilling their promise ridiculously fast.

"Some of these results are really astonishing; almost jaw-dropping. And these drugs may be applicable to many different cancer types, including ones that are hard to treat, such as lung cancer.

"Cancers adapt to treatments, and when they come back they are harder to treat. Can we dream about actually curing some of our patients with very advanced cancer? Once we get the immune system attacking the cancer, can it act independently to keep the cancer under control? We don't have all the answers yet, but that's what we're looking at."

Pembrolizumab is a synthetic antibody that blocks a biological pathway called programmed cell death 1 (PD-1) which cancers activate to suppress the immune system.

In healthy individuals, PD-1 is part of the process that applies a "brake" to the immune system and prevents it running out of control.

Without the brake, there is a risk of a harmful inflammatory reaction - a potential serious side-effect of the new drugs.

Pembrolizumab was generally "well tolerated" by the trial patients, according to Dr Chao, but he said responses varied widely between individuals.

Results from the trial were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Clinicians do not yet know the true extent of how pembrolizumab might affect survival. After 18 months, 62% of patients were still alive and undergoing treatment.

In addition, around 80% of patients responded to the drug - an unusually high proportion.

A total of 72% experienced tumour shrinkage, including 39% whose tumours were more than halved in size, according to one kind of assessment.

Additional data showed that the drug also reduced the size of advanced non-small cell lung cancers by up to 47%.

Pembrolizumab's manufacturer, the pharmaceutical company Merck Sharp & Dohme, is expected to apply for a European licence to market the drug within months.

Each year, around 13,300 people in the UK are diagnosed with melanoma - more than a third of them aged under 55.

Gillian Nuttall, founder of the charity Melanoma UK, said: "Advanced melanoma is a terrible disease with a poor prognosis. Pembrolizumab represents the latest advance in a whole raft of new treatments in advanced melanoma which have come through over the past few years.

"The pembrolizumab results are really exciting and could represent a turning point for patients affected by advanced melanoma, giving them a greater chance of survival."

PA

Sport
The giant banner displayed by Legia Warsaw supporters last night
football
News
news
Voices
The Ukip leader has consistently refused to be drawn on where he would mount an attempt to secure a parliamentary seat
voicesNigel Farage: Those who predicted we would lose momentum heading into the 2015 election are going to have to think again
News
Angelina Jolie with her father Jon Voight
people
PROMOTED VIDEO
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Life and Style
ebooksFrom the lifespan of a slug to the distance to the Sun: answers to 500 questions from readers
Arts and Entertainment
Cara Delevingne made her acting debut in Anna Karenina in 2012
film Cara Delevingne 'in talks' to star in Zoolander sequel
News
Melissa and Joan Rivers together at an NBC event in May 2014
peopleDaughter Melissa thanks fans for 'outpouring of support'
Life and Style
tech
Life and Style
life
Life and Style
One in six drivers cannot identify a single one of the main components found under the bonnet of an average car
motoringOne in six drivers can't carry out basic under-bonnet checks
News
i100
Voices
Pupils educated at schools like Eton (pictured) are far more likely to succeed in politics and the judiciary, the report found
voices
Arts and Entertainment
Simon Cowell is less than impressed with the Strictly/X Factor scheduling clash
tvSimon Cowell blasts BBC for breaking 'gentlemen's agreement' in scheduling war
News
peopleWrestling veteran drifting in and out of consciousness
Arts and Entertainment
Shady character: Jon Hamm as sports agent JB Bernstein in Million Dollar Arm
filmReview: Jon Hamm finally finds the right role on the big screen in Million Dollar Arm
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Business Analyst,HR,Halifax,£400-450pd

    £400 - £450 per day + competitive: Orgtel: My client, a leading bank, is curre...

    Project Coordinator - Cisco Partner - £110 p/d

    £110 per day + competitive: Orgtel: Project Coordinator (SC Cleared), Cisco Go...

    Recruitment Consultants - IT - Trainee / Experienced

    £20000 - £30000 per annum + OTE £40-50K first year: SThree: The SThree group i...

    Primary teachers needed for supply in Huntingdon

    £21000 - £35000 per annum: Randstad Education Cambridge: Primary teachers need...

    Day In a Page

    Ukraine crisis: The phoney war is over as Russian troops and armour pour across the border

    The phoney war is over

    Russian troops and armour pour into Ukraine
    Potatoes could be off the menu as crop pests threaten UK

    Potatoes could be off the menu as crop pests threaten UK

    The world’s entire food system is under attack - and Britain is most at risk, according to a new study
    Gangnam smile: why the Chinese are flocking to South Korea to buy a new face

    Gangnam smile: why the Chinese are flocking to South Korea to buy a new face

    Seoul's plastic surgery industry is booming thanks to the popularity of the K-Pop look
    From Mozart to Orson Welles: Creative geniuses who peaked too soon

    Creative geniuses who peaked too soon

    After the death of Sandy Wilson, 90, who wrote his only hit musical in his twenties, John Walsh wonders what it's like to peak too soon and go on to live a life more ordinary
    Caught in the crossfire of a cyber Cold War

    Caught in the crossfire of a cyber Cold War

    Fears are mounting that Vladimir Putin has instructed hackers to target banks like JP Morgan
    Salomé's feminine wiles have inspired writers, painters and musicians for 2,000 years

    Salomé: A head for seduction

    Salomé's feminine wiles have inspired writers, painters and musicians for 2,000 years. Now audiences can meet the Biblical femme fatale in two new stage and screen projects
    From Bram Stoker to Stanley Kubrick, the British Library's latest exhibition celebrates all things Gothic

    British Library celebrates all things Gothic

    Forthcoming exhibition Terror and Wonder: The Gothic Imagination will be the UK's largest ever celebration of Gothic literature
    The Hard Rock Café's owners are embroiled in a bitter legal dispute - but is the restaurant chain worth fighting for?

    Is the Hard Rock Café worth fighting for?

    The restaurant chain's owners are currently embroiled in a bitter legal dispute
    Caribbean cuisine is becoming increasingly popular in the UK ... and there's more to it than jerk chicken at carnival

    In search of Caribbean soul food

    Caribbean cuisine is becoming increasingly popular in the UK ... and there's more to it than jerk chicken at carnival
    11 best face powders

    11 best face powders

    Sweep away shiny skin with our pick of the best pressed and loose powder bases
    England vs Norway: Roy Hodgson's hands tied by exploding top flight

    Roy Hodgson's hands tied by exploding top flight

    Lack of Englishmen at leading Premier League clubs leaves manager hamstrung
    Angel Di Maria and Cristiano Ronaldo: A tale of two Manchester United No 7s

    Di Maria and Ronaldo: A tale of two Manchester United No 7s

    They both inherited the iconic shirt at Old Trafford, but the £59.7m new boy is joining a club in a very different state
    Israel-Gaza conflict: No victory for Israel despite weeks of death and devastation

    Robert Fisk: No victory for Israel despite weeks of devastation

    Palestinians have won: they are still in Gaza, and Hamas is still there
    Mary Beard writes character reference for Twitter troll who called her a 'slut'

    Unlikely friends: Mary Beard and the troll who called her a ‘filthy old slut’

    The Cambridge University classicist even wrote the student a character reference
    America’s new apartheid: Prosperous white districts are choosing to break away from black cities and go it alone

    America’s new apartheid

    Prosperous white districts are choosing to break away from black cities and go it alone